It happened again on Thursday morning, when Cigna Group reported quarterly earnings. The results missed estimates and management’s financial guidance for next year was lower than Wall Street expected.
Cigna Group CEO David Cordani said the company will make investments this year to improve patient and provider experiences with the insurer.
Shares of Cigna Group slipped 6.70% to $282.98 Thursday, on what proved to be an all-around favorable trading session for the stock market, with the S&P 500 Index rising 0.53% to 6,071.17 and the Dow Jones Industrial Average rising 0.
Cigna Group shares slumped after the health insurer reported cost pressures from surprisingly high catastrophic medical claims that are likely to persist.Most Read from BloombergManhattan’s Morning Co
Cigna's Evernorth Health Services said on Wednesday its actions will enhance transparency about the company's negotiations.
Pharmacy benefit managers overcharged for specialty generic medications — in many cases by hundreds and thousands of percent — for billions in profits, according to a report from the Federal Trade Commission,
Fresh off underperforming Wall Street’s expectations in the fourth quarter, Cigna said it would work to lower costs for its customers amid widespread discontent with the healthcare system.
Between 2017 and 2022, UnitedHealth Group’s Optum, Cigna’s Express Scripts and CVS Health’s CVS Caremark marked up their prices by hundreds — and in some cases, thousands — of percent, resulting in $7.3 billion in revenue above cost.
Cigna executives kicked off Thursday’s earnings call by responding to pharmacy benefit manager critics with a number of reforms.
(Bloomberg) -- Units of CVS Health Corp., Cigna Group and UnitedHealth Group Inc. charged significantly more than the national average acquisition cost for dozens of specialty generic drugs, bringing in more than $7.3 billion in “excess” revenue over ...
Cigna Group shares fell sharply after the health insurer reported fourth-quarter profit that was dragged down by medical costs, a trend that’s concerned investors in the sector for months.
According to Bloomberg, a top Cigna executive said it will prevent patients from paying the full list price for drugs, or more than their employer has contributed.